Spotlight Innovation Launches Development of STL-182 to Treat Spinal Muscular Atrophy

04:48 EDT 19 Oct 2016 | PR Newswire
This article has expired, however you can still download the PDF.
WEST DES MOINES, Iowa, Oct. 19, 2016 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT) today announced that it has obtained an exclusive, worldwide license from Indiana University Research and Technology Corp. to commercialize STL-182, an orally...

Other Sources for this Article


More From BioPortfolio on "Spotlight Innovation Launches Development of STL-182 to Treat Spinal Muscular Atrophy"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...